Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has ...

Microsoft Scientific Discovery is an AI-powered research-focused platform designed for scientists, research institutions, and ...

Artificial intelligence and robotics are revolutionizing drug discovery by automating laboratory processes and enabling rapid ...

Insilico Medicine ("Insilico"), in collaboration with research partner at Huadong Medicine Company, today announced the ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...

Dr. D. Wade Clapp's work with British biotech company Healx dates to 2019. Photo by Liz Kaye, Indiana University Indiana ...

Startup Persist AI, which launched a cloud lab to accelerate pharmaceutical formulation development, raised $12 million in a ...

Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor ...